IL293238A - Cela-1 inhibition for treatment of lung disease - Google Patents

Cela-1 inhibition for treatment of lung disease

Info

Publication number
IL293238A
IL293238A IL293238A IL29323822A IL293238A IL 293238 A IL293238 A IL 293238A IL 293238 A IL293238 A IL 293238A IL 29323822 A IL29323822 A IL 29323822A IL 293238 A IL293238 A IL 293238A
Authority
IL
Israel
Prior art keywords
residues
cela1
lung
human
antibody
Prior art date
Application number
IL293238A
Other languages
English (en)
Hebrew (he)
Original Assignee
Childrens Hospital Med Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Med Ct filed Critical Childrens Hospital Med Ct
Publication of IL293238A publication Critical patent/IL293238A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21036—Pancreatic elastase (3.4.21.36)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL293238A 2019-11-26 2020-11-23 Cela-1 inhibition for treatment of lung disease IL293238A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962940302P 2019-11-26 2019-11-26
US202063009134P 2020-04-13 2020-04-13
PCT/US2020/061774 WO2021108302A1 (en) 2019-11-26 2020-11-23 Cela-1 inhibition for treatment of lung disease

Publications (1)

Publication Number Publication Date
IL293238A true IL293238A (en) 2022-07-01

Family

ID=76129647

Family Applications (1)

Application Number Title Priority Date Filing Date
IL293238A IL293238A (en) 2019-11-26 2020-11-23 Cela-1 inhibition for treatment of lung disease

Country Status (6)

Country Link
US (1) US20230002510A1 (enExample)
EP (1) EP4065167A4 (enExample)
JP (1) JP2023502259A (enExample)
AU (1) AU2020394374A1 (enExample)
IL (1) IL293238A (enExample)
WO (1) WO2021108302A1 (enExample)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1646160A (zh) * 2002-03-13 2005-07-27 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
US8501449B2 (en) * 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
GB0916576D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
CN107690429B (zh) * 2015-04-07 2022-02-25 Ela制药有限公司 用于治疗和/或预防细胞或组织坏死的组合物，其特异性靶向组织蛋白酶c和/或cela1和/或cela3a和/或与其结构相关的酶
EP3737666A4 (en) * 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES

Also Published As

Publication number Publication date
US20230002510A1 (en) 2023-01-05
JP2023502259A (ja) 2023-01-23
WO2021108302A1 (en) 2021-06-03
EP4065167A4 (en) 2024-03-27
AU2020394374A9 (en) 2022-06-16
EP4065167A1 (en) 2022-10-05
AU2020394374A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
US12005117B2 (en) Methods for inhibiting fibrosis in a subject in need thereof
JP2020504076A (ja) 抗ｔｌ１ａモノクローナル抗体の中和
US20230212276A1 (en) Monoclonal antibody and antigens for diagnosing and treating lung disease and injury
US20210079116A1 (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
EP1135413A2 (en) Proteins that bind angiogenesis-inhibiting proteins, compoisitions and methods of use thereof
MX2011011023A (es) Tratamiento de cancer de ovarios usando un agente anti-cancer conjugado con un analogo de angiopep-2.
CN119185544A (zh) 用于治疗和/或预防冠状病毒诱导的急性呼吸窘迫综合征的抑制masp-2的方法
JP2014529606A (ja) 血液凝固促進に使用するための化合物
WO2018071701A1 (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
TW202402790A (zh) 減少呼吸系統感染之方法
DaSilva et al. Cleavage of osteopontin by matrix metalloproteinase-12 modulates experimental autoimmune encephalomyelitis disease in C57BL/6 mice
AU2020200574A1 (en) Methods and products for preventing and/or treating metastatic cancer
US20230002510A1 (en) Cela-1 inhibition for treatment of lung disease
US11629186B2 (en) Anti-CCL8 antibodies and uses thereof
EP3042667A1 (en) Dpp-4-targeting vaccine for treating diabetes
WO2017019454A2 (en) Identification of novel anti-fibrotic peptide in c-terminal region of the met receptor tyrosine kinase
JP4225487B2 (ja) メグシン中和モノクローナル抗体
US9909108B2 (en) Preparations and methods for treating malignancies
JP2009539853A (ja) 抗プラスミン切断酵素の基質および阻害剤ならびにその使用
KR20140045345A (ko) 질환을 치료하고, 진단하고, 모니터링하기 위한 조성물과 방법
WO2013013075A2 (en) Peptides shared among lethal cancers and therapeutic compositions comprising said peptides
WO2020247703A1 (en) Methods and compositions for treatment of neurodegeneration
EA043102B1 (ru) Способ уменьшения протеинурии у человека, страдающего от иммуноглобулин а нефропатии
EA049345B1 (ru) Способ подавления фиброза у нуждающегося в этом субъекта
EA049795B1 (ru) Способ подавления фиброза у нуждающегося в этом субъекта